Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Apolipoprotein E enhances endothelial-NO production by modulating caveolin 1 interaction with endothelial NO synthase.

Yue L, Bian JT, Grizelj I, Cavka A, Phillips SA, Makino A, Mazzone T.

Hypertension. 2012 Oct;60(4):1040-6. doi: 10.1161/HYPERTENSIONAHA.112.196667. Epub 2012 Aug 20.

2.

Nitric oxide-dependent Src activation and resultant caveolin-1 phosphorylation promote eNOS/caveolin-1 binding and eNOS inhibition.

Chen Z, Bakhshi FR, Shajahan AN, Sharma T, Mao M, Trane A, Bernatchez P, van Nieuw Amerongen GP, Bonini MG, Skidgel RA, Malik AB, Minshall RD.

Mol Biol Cell. 2012 Apr;23(7):1388-98. doi: 10.1091/mbc.E11-09-0811. Epub 2012 Feb 9.

3.

The trafficking/interaction of eNOS and caveolin-1 induced by insulin modulates endothelial nitric oxide production.

Wang H, Wang AX, Liu Z, Chai W, Barrett EJ.

Mol Endocrinol. 2009 Oct;23(10):1613-23. doi: 10.1210/me.2009-0115. Epub 2009 Jul 16.

4.

Chronic administration of BMS309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells.

Lee MY, Li H, Xiao Y, Zhou Z, Xu A, Vanhoutte PM.

Br J Pharmacol. 2011 Apr;162(7):1564-76. doi: 10.1111/j.1476-5381.2010.01158.x.

5.

Deciphering the binding of caveolin-1 to client protein endothelial nitric-oxide synthase (eNOS): scaffolding subdomain identification, interaction modeling, and biological significance.

Trane AE, Pavlov D, Sharma A, Saqib U, Lau K, van Petegem F, Minshall RD, Roman LJ, Bernatchez PN.

J Biol Chem. 2014 May 9;289(19):13273-83. doi: 10.1074/jbc.M113.528695. Epub 2014 Mar 19.

6.

Antiatherosclerotic effects of small-molecular-weight compounds enhancing endothelial nitric-oxide synthase (eNOS) expression and preventing eNOS uncoupling.

Wohlfart P, Xu H, Endlich A, Habermeier A, Closs EI, Hübschle T, Mang C, Strobel H, Suzuki T, Kleinert H, Förstermann U, Ruetten H, Li H.

J Pharmacol Exp Ther. 2008 May;325(2):370-9. doi: 10.1124/jpet.107.128009. Epub 2008 Feb 5.

7.

Caveolin-1 mediates endotoxin inhibition of endothelin-1-induced endothelial nitric oxide synthase activity in liver sinusoidal endothelial cells.

Kwok W, Lee SH, Culberson C, Korneszczuk K, Clemens MG.

Am J Physiol Gastrointest Liver Physiol. 2009 Nov;297(5):G930-9.

8.

Caveolin-1 regulates NF-kappaB activation and lung inflammatory response to sepsis induced by lipopolysaccharide.

Garrean S, Gao XP, Brovkovych V, Shimizu J, Zhao YY, Vogel SM, Malik AB.

J Immunol. 2006 Oct 1;177(7):4853-60.

9.

Amlodipine increases endothelial nitric oxide release by modulating binding of native eNOS protein complex to caveolin-1.

Sharma A, Trane A, Yu C, Jasmin JF, Bernatchez P.

Eur J Pharmacol. 2011 Jun 1;659(2-3):206-12. doi: 10.1016/j.ejphar.2011.03.028. Epub 2011 Apr 2.

PMID:
21463621
10.

ATP-binding cassette transporter G1 and high-density lipoprotein promote endothelial NO synthesis through a decrease in the interaction of caveolin-1 and endothelial NO synthase.

Terasaka N, Westerterp M, Koetsveld J, Fernández-Hernando C, Yvan-Charvet L, Wang N, Sessa WC, Tall AR.

Arterioscler Thromb Vasc Biol. 2010 Nov;30(11):2219-25. doi: 10.1161/ATVBAHA.110.213215. Epub 2010 Aug 26.

11.

Caveolin-1 scaffolding domain residue phenylalanine 92 modulates Akt signaling.

Trane AE, Hiob MA, Uy T, Pavlov D, Bernatchez P.

Eur J Pharmacol. 2015 Nov 5;766:46-55. doi: 10.1016/j.ejphar.2015.09.033. Epub 2015 Sep 25.

PMID:
26409042
12.

eNOS protects from atherosclerosis despite relevant superoxide production by the enzyme in apoE mice.

Ponnuswamy P, Schröttle A, Ostermeier E, Grüner S, Huang PL, Ertl G, Hoffmann U, Nieswandt B, Kuhlencordt PJ.

PLoS One. 2012;7(1):e30193. doi: 10.1371/journal.pone.0030193. Epub 2012 Jan 23.

13.

Caveolin-1-eNOS signaling promotes p190RhoGAP-A nitration and endothelial permeability.

Siddiqui MR, Komarova YA, Vogel SM, Gao X, Bonini MG, Rajasingh J, Zhao YY, Brovkovych V, Malik AB.

J Cell Biol. 2011 May 30;193(5):841-50. doi: 10.1083/jcb.201012129.

14.

A noninhibitory mutant of the caveolin-1 scaffolding domain enhances eNOS-derived NO synthesis and vasodilation in mice.

Bernatchez P, Sharma A, Bauer PM, Marin E, Sessa WC.

J Clin Invest. 2011 Sep;121(9):3747-55. doi: 10.1172/JCI44778. Epub 2011 Aug 1. Erratum in: J Clin Invest. 2012 Jan;122(1):419.

15.

PPARgamma1-induced caveolin-1 enhances cholesterol efflux and attenuates atherosclerosis in apolipoprotein E-deficient mice.

Hu Q, Zhang XJ, Liu CX, Wang XP, Zhang Y.

J Vasc Res. 2010;47(1):69-79. doi: 10.1159/000235927. Epub 2009 Sep 3.

PMID:
19729954
16.

Genetic evidence supporting a critical role of endothelial caveolin-1 during the progression of atherosclerosis.

Fernández-Hernando C, Yu J, Suárez Y, Rahner C, Dávalos A, Lasunción MA, Sessa WC.

Cell Metab. 2009 Jul;10(1):48-54. doi: 10.1016/j.cmet.2009.06.003.

17.

Upregulation of caveolin-1 contributes to aggravated high-salt diet-induced endothelial dysfunction and hypertension in type 1 diabetic rats.

Li X, Xing W, Wang Y, Mi C, Zhang Z, Ma H, Zhang H, Gao F.

Life Sci. 2014 Sep 15;113(1-2):31-9. doi: 10.1016/j.lfs.2014.07.027. Epub 2014 Jul 30.

PMID:
25086377
18.

Endothelial-specific overexpression of caveolin-1 accelerates atherosclerosis in apolipoprotein E-deficient mice.

Fernández-Hernando C, Yu J, Dávalos A, Prendergast J, Sessa WC.

Am J Pathol. 2010 Aug;177(2):998-1003. doi: 10.2353/ajpath.2010.091287. Epub 2010 Jun 25.

19.

Irisin protects against endothelial injury and ameliorates atherosclerosis in apolipoprotein E-Null diabetic mice.

Lu J, Xiang G, Liu M, Mei W, Xiang L, Dong J.

Atherosclerosis. 2015 Dec;243(2):438-48. doi: 10.1016/j.atherosclerosis.2015.10.020. Epub 2015 Oct 19.

PMID:
26520898
20.

Supplemental Content

Support Center